Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 14 Best Small Cap Stocks to Buy Right Now. On August 25, Raymond James increased the price target on Dyne Therapeutics, Inc. (NASDAQ:DYN) stock from $31 to $35, maintaining its Buy rating.
Martin Auster from Raymond James upgraded the price target on DYN as he remains optimistic on the upcoming DYNE-251 registrational cohort readout expected in late 2025. Auster sees potential in the upcoming investigational exon-skipping therapy for Duchenne Muscular Dystrophy (DMD). The company expects a Biologics License Application (BLA) filing in early 2026. The analyst’s confidence is based on three major factors, including the differentiated profile of DYNE-251 compared to Exondys 51, a competing therapy in the DMD treatment space.
On August 4, Dyne Therapeutics announced the FDA approval for the treatment of patients with DMD. Auster believes in a pathway to accelerated approval for the therapy, which could boost its market entry if successful in clinical trials.
“This Breakthrough Therapy Designation for DYNE-251 is a testament to its potential as a next-generation therapy designed to bring meaningful functional improvement to individuals with DMD for whom exon 51 skipping can lead to the production of near full-length dystrophin,” said Doug Kerr, M.D., Ph.D., chief medical officer of Dyne Therapeutics.
As of September 5, Dyne Therapeutics, Inc.’s average price target of $38, based on analysts’ estimates, implies an upside of nearly 167.23% from current levels.
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company that focuses on discovering and developing therapeutics for neuromuscular diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
